Summary of Conference Call Notes Company and Industry Overview - **Company**: Anke Bio (安科生物) - **Industry**: Pharmaceutical and Biotechnology, focusing on innovative drugs and gene therapy Key Points and Arguments 1. **Pharmaceutical Sector Performance**: The pharmaceutical sector has shown strong excess returns despite market pressures, with innovative drugs and traditional Chinese medicine performing particularly well, indicating a sustained bull market in pharmaceuticals [2][3] 2. **Focus on Innovative Drugs**: The clear future direction for the pharmaceutical industry is innovative drugs, with a focus on leading companies and those with significant catalysts or market potential [4][5] 3. **Anke Bio's CD7 CAR-T Therapy**: Anke Bio's CD7 CAR-T therapy for T-cell lymphoma and leukemia shows a total response rate (ORR) of 84.6% and a complete response rate of 77%, with promising durability [2][9] 4. **Market Potential for CD7 CAR-T**: The domestic market for relapsed/refractory T-cell lymphoma and leukemia is estimated at 2.1 billion yuan, with potential expansion to 5 billion yuan if additional indications are successful [10] 5. **Gene Therapy Developments**: AAV gene therapy in ophthalmology has advantages such as immune evasion and lower dosage requirements, with significant projects like Regenexbile and AbbVie’s RGX-314 expected to complete key trials by 2025 [14][15] 6. **Investment Recommendations**: Recommended stocks include Kangfang Biotech, Shanghai Pharmaceuticals, Anke Bio, and others, with a focus on companies with strong short-term performance or potential rebounds [6][7] 7. **Valuation of Anke Bio**: Anke Bio's current market cap is approximately 20 billion yuan, with potential to double to 40 billion yuan as the innovative drug segment is not fully valued [12] 8. **Innovative Pipeline**: Anke Bio has multiple innovative pipelines, including HER2 monoclonal antibodies and PD-L1/4-1BB bispecific antibodies, indicating a broad future development outlook [11][23] Additional Important Insights 1. **Clinical Trial Progress**: Anke Bio's CD7 CAR-T therapy is leading in domestic clinical progress, with significant catalysts expected soon [9] 2. **Safety and Efficacy**: The adverse reactions for Anke Bio's therapy are comparable to existing CAR-T therapies, making it a viable option for patients [10][20] 3. **Global Gene Therapy Landscape**: The AAV gene therapy field is seeing significant interest from major pharmaceutical companies, with a focus on rare diseases and expanding into common diseases [18][22] 4. **Emerging Companies**: Companies like Kanghong Pharma and TEBIO are making notable advancements in AAV gene therapy, particularly in ophthalmology [19][22] This summary encapsulates the key insights from the conference call, highlighting the performance and future potential of Anke Bio and the broader pharmaceutical industry.

金融界8月4日消息，上证指数低开高走，中证1000医药卫生指数 (1000医药，H30444)报13651.50点。 从指数持仓来看，中证1000医药卫生指数十大权重分别为：博瑞医药（3.51%）、通化金马 （2.65%）、泽璟制药（2.51%）、众生药业（1.75%）、昭衍新药（1.7%）、安科生物（1.66%）、一 品红（1.63%）、佐力药业（1.59%）、福瑞股份（1.39%）、东诚药业（1.33%）。 从中证1000医药卫生指数持仓的市场板块来看，上海证券交易所占比55.62%、深圳证券交易所占比 44.38%。 从中证1000医药卫生指数持仓样本的行业来看，化学药占比36.28%、医疗器械占比19.30%、中药占比 17.00%、生物药品占比14.30%、医疗商业与服务占比7.16%、制药与生物科技服务占比5.94%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收 购、合并、分拆等情形的处理，参照计算与维护细则处理。当中证1000指数调整样本时，中证1000行 ...

截至8月4日开盘一小时，主力资金流出前20的股票分别为：中际旭创（-4.43亿元）、海康威视（-3.53 亿元）、胜宏科技（-2.73亿元）、西藏天路（-2.59亿元）、天府文旅（-2.50亿元）、药明康德（-2.41 亿元）、比亚迪（-2.34亿元）、步步高（-2.32亿元）、捷佳伟创（-2.29亿元）、东芯股份（-2.25亿 元）、上海电影（-2.11亿元）、安科生物（-2.02亿元）、新易盛（-1.85亿元）、深桑达Ａ（-1.78亿 元）、东山精密（-1.78亿元）、天孚通信（-1.77亿元）、中国电影（-1.58亿元）、万兴科技（-1.57亿 元）、昆仑万维（-1.56亿元）、通威股份（-1.43亿元）。 本文源自：金融界 作者：金股通 ...

Group 1 - Pharmaceutical stocks continued to decline in early trading, with companies like Kexing Pharmaceutical and Bioventure dropping over 11% [1] - Other companies such as Aoxiang Pharmaceutical, Shenlian Biological, Anke Biotechnology, Zhongsheng Pharmaceutical, and Haichuang Pharmaceutical experienced declines of over 6% [1]

Investment Rating - The report maintains an "Outperform" rating for the industry [7] Core Insights - The domestic CD7 CAR-T therapy is expected to achieve breakthroughs, with a focus on Anke Biopharma [5][17] - The market for innovative drugs continues to show strong performance, with significant trading volume and interest in new drug developments [5][41] Market Review - The CITIC Pharmaceutical Index rose by 2.7% during the week of July 28 to August 1, 2025, outperforming the CSI 300 Index by 4.5 percentage points, ranking second among CITIC's primary industry classifications [4][41] - Year-to-date, the CITIC Pharmaceutical and Biotech Index has increased by 22.8%, surpassing the CSI 300 Index by 19.7 percentage points [4][41] - The top five performing stocks for the week included Nanjing New Drug (up 78%), Lide Man (up 46.4%), Chenxin Pharmaceutical (up 40.9%), Qizheng Tibetan Medicine (up 40%), and Guangshengtang (up 36.4%) [4][56] Focus on CD7 CAR-T Therapy - Relapsed/refractory T-ALL/LBL has a poor prognosis, with a median survival of only 6 months and limited treatment options available [5][17][18] - Anke Biopharma's PA3-17 is leading in domestic clinical trials for CD7 CAR-T therapy, currently in Phase II, showing an overall response rate (ORR) of 84.6% and a complete response (CR) rate of 76.9% in Phase I trials [5][27][26] - The potential for PA3-17 to become the first approved product targeting T-cell malignancies in China is significant, with opportunities for expanding indications [5][26][33] Investment Recommendations - The report suggests focusing on a combination of innovative drugs, particularly those with commercial capabilities and rich pipelines, as well as medical devices that are expected to see a turnaround in fundamentals [5][41] - Recommended stocks for August include Heng Rui Pharmaceutical, Kangfang Biopharma, Kanghong Pharmaceutical, and others [5][12]

Market Overview - The Shanghai Composite Index fell by 0.94% this week, with six industries experiencing gains, led by the pharmaceutical and biotechnology sector, which rose by 2.95% [1] - The coal and non-ferrous metals industries saw the largest declines, with drops of 4.67% and 4.62% respectively [1] Fund Flow Analysis - A total of 211.86 billion yuan was net withdrawn from the two markets this week, with only the banking sector seeing a net inflow of 4.33 billion yuan [1] - The non-ferrous metals industry had the highest net outflow, totaling 25.99 billion yuan, followed by the computer industry with a net outflow of 20.45 billion yuan [1][2] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector had a net outflow of 4.68 billion yuan this week, despite a price increase of 2.95% [3] - Out of 474 stocks in this sector, 323 stocks rose, with notable gainers including Nanjing New Pharmaceutical (up 78.01%), Lide Man (up 46.45%), and Chenxin Pharmaceutical (up 40.88%) [3] - The sector also saw 36 stocks with net outflows exceeding 100 million yuan, with WuXi AppTec leading at 1.98 billion yuan [3][4] Top Gainers and Losers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: up 29.52% with a net inflow of 1.01 billion yuan - Anke Bio: up 25.93% with a net inflow of 0.36 billion yuan - Lianhuan Pharmaceutical: up 15.99% with a net inflow of 0.34 billion yuan [3] - The top losers included: - WuXi AppTec: down 4.64% with a net outflow of 1.98 billion yuan - Borui Pharmaceutical: down 0.14% with a net outflow of 0.71 billion yuan - Kanglong Chemical: up 0.33% with a net outflow of 0.51 billion yuan [4]

Market Overview - The Shanghai Composite Index fell by 1.18% to close at 3573.21 points, with a daily high of 3606.37 points [1] - The Shenzhen Component Index decreased by 1.73% to 11009.77 points, reaching a maximum of 11223.64 points [1] - The ChiNext Index dropped by 1.66% to 2328.31 points, with a peak of 2394.22 points [1] Margin Trading and Securities Lending - The total margin trading and securities lending balance in the Shanghai and Shenzhen markets was 19784.97 billion yuan, with a financing balance of 19646.98 billion yuan and a securities lending balance of 137.99 billion yuan [2] - The margin trading and securities lending balance increased by 0.9 billion yuan compared to the previous trading day [2] - The Shanghai market's margin trading balance was 10106.42 billion yuan, decreasing by 5.54 billion yuan from the previous day, while the Shenzhen market's balance was 9678.55 billion yuan, increasing by 6.45 billion yuan [2] Top Margin Buying Stocks - The top three stocks by margin buying amount were: - Xinyi Technology (300502.SZ) with 23.63 billion yuan - Zhongji Xuchuang (300308.SZ) with 20.8 billion yuan - Shenghong Technology (300476.SZ) with 17.1 billion yuan [3] Fund Issuance - Two new funds were launched: Huafu Medical Innovation Mixed Initiation A and Huafu Medical Innovation Mixed Initiation C [4] Top Net Buying by Brokerage Firms - The top ten net buying amounts by brokerage firms were: - Nord Shares (600110.SH) with 422.75 million yuan - Great Wall Military Industry (601606.SH) with 385.34 million yuan - Yidian Tianxia (301171.SZ) with 375.30 million yuan [6][7]

Market Performance - On the last trading day of July, all three major A-share indices fell by over 1%, with the Shanghai Composite Index closing below 3600 points at 3573.21, down 1.18% [1] - The Shenzhen Component Index dropped 1.73% to 11009.77, while the ChiNext Index decreased by 1.66% to 2328.31 [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.96 trillion yuan [1] Sector Performance - The sectors that saw gains included liquid cooling IDC, assisted reproduction, Google, biopharmaceuticals, chemical pharmaceuticals, and computers [1] - Conversely, sectors that experienced declines included aquaculture, PTA, iron ore, energy metals, steel, and minor metals [1] Notable Stocks - The AI sector showed strong fluctuations, with Yidian Tianxia (301171) hitting the 20% daily limit up [1] - The liquid cooling server sector performed well, with Sihua New Materials (301489) also reaching the 20% limit up, alongside Yingweike (002837) and Chunz中科技 (603516) [1] - The assisted reproduction sector continued to strengthen, with Gongtong Pharmaceutical (300966) and Anke Biotechnology (300009) both hitting the 20% limit up, while Hanshang Group (600774) also reached the limit [1] - The steel sector faced adjustments, with Baogang Co. (600010) dropping over 8% [1] - The coal sector declined across the board, with Antai Group (600408) falling over 7% [1] Market Outlook - According to Jifeng Investment Advisory, the A-share market is expected to continue a structural trend in August, supported by the intensive disclosure of mid-term performance and ongoing policy efforts, favoring industries with high earnings certainty [1] - Dongfang Securities noted that the current A-share market is in a sustained upward trend with ample trading volume, attracting new capital, and maintaining a cautiously optimistic sentiment without immediate risk of reversal [2]

7月31日，上证指数下跌1.18%，深证成指下跌1.73%，创业板指下跌1.66%。盘后龙虎榜数据显示，共 有50只个股因当日异动登上龙虎榜，资金净流入最多的是诺德股份（600110.SH），达4.23亿元。 据21投资通智能监测，26只个股龙虎榜出现了机构的身影，北向资金参与龙虎榜中的个股共涉及16只。 4.23亿资金抢筹诺德股份，1.98亿资金出逃亚太药业 50只上榜的龙虎榜个股中，31只个股被净买入，19只个股被净卖出。其中，资金净买入最多的是诺德股 份，达4.23亿元，占总成交金额的22.01%。诺德股份当日收盘上涨10.02%，换手率为17.98%。 而龙虎榜中资金净流出最多的是亚太药业（002370.SZ），被净卖出为1.98亿元，占总成交金额的 10.06%。亚太药业收盘下跌6.14%，换手率为37.4%。 机构净卖出的个股中，金额最多的是东芯股份（688110.SH），当日收盘上涨19.99%，换手率为 7.22%。 北向资金净买入11股，净卖出5股 7月31日，北向资金参与龙虎榜中的个股共有16只，合计净买入7.96亿元。其中沪股通净买入6 股，净卖 出2 股，合计净买入6.2亿元；深股通净 ...

高换手率个股中，1股公布了半年报，净利润同比增幅较高的是华康洁净，净利润增幅为273.48%。公 布上半年业绩预告的共有7只。业绩预告类型来看，预增有5只，预盈有1只。以净利润增幅中值来看， 净利润增幅最高的是翰宇药业，预计净利润中值为1.52亿元，同比增幅为1567.36%；硕贝德、满坤科 技、威尔高紧随其后，预计净利润增幅中值为947.88%、66.81%、21.71%。（数据宝） 7月31日创业板换手率居前个股 证券时报·数据宝统计显示，换手率方面，创业板今日平均换手率为4.90%，换手率区间分布显示，换手 率超过20%的有59只，换手率10%~20%之间的有181只，换手率5%~10%的有328只，换手率1%~5%的有 783只，换手率不足1%的有32只。 换手率最高的是北方长龙，该股今日收盘上涨17.22%，全天换手率66.12%，成交额14.82亿元；其次是 凯格精机，该股今日收盘上涨10.45%，全天换手率39.97%，成交额7.20亿元；换手率居前的还有恒宇信 通、新恒汇、易点天下等，换手率分别为38.26%、37.68%、37.61%。 从市场表现看，高换手率股中，今日上涨的有42只，涨幅居 ...